All podcasts

CAR-T Therapies to Reverse Cardiac Fibrosis

Injury to heart tissue results in non-functional scar tissue that compromises cardiac function. A new approach combines targeted lipid nanoparicles and mRNAs to reprogram immune cells to seek and destroy the pathogenic fibroblasts that limit heart function. Results from mice are promising, and indicate that these approaches may have significant value in treating a suite of human disorders.

Jul 8, 2022 by Dr. Kevin Folta in Talking Biotech

Apple podcasts link Google podcasts link Spotify podcasts link

Injury to organs frequently results in impaired function due to the formation of scar tissue. Heart attacks and chronic high blood pressure can induce the formation of pathogenic fibroblasts, cells that lose their original function, yet maintain some structural element of the injured tissue. The formation of fibrogenic tissue affects a significant portion of the population, and contributes to decline associated with many diseases, such as congestive heart failure or liver cirrhosis. A new technology uses targeted lipid nanoparticles to reprogram T-cells to attack pathogenic fibroblasts.


Get your whole lab on the same page today.

Learn more